The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The healthcare sector saw significant activity as Oruka Therapeutics shares surged 43.4% in premarket trading following successful mid-stage study results for its experimental psoriasis drug, which met its primary goal within 16 weeks. This follows Novartis securing European Commission approval for Rhapsido as an oral treatment for chronic spontaneous urticaria (CSU). Clinical data from the REMIX 1 and 2 studies demonstrated significant symptom improvement as early as Week 1, maintaining a favorable safety profile. As a targeted oral BTKi treatment, Rhapsido addresses a substantial market of nearly 4 million CSU sufferers across Europe and is already recommended in the 2026 International Urticaria Guideline. These combined developments highlight a period of high clinical success, with both companies poised for significant therapeutic portfolio expansion and revenue growth. Analysts view these milestones as major successes for the R&D pipelines of both Oruka and Novartis.
Sign in to access this content
Sign In